Search results for "ANTIBIOTICS"

showing 10 items of 472 documents

Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study

2007

Abstract Background The objective of this study is to evaluate the efficacy and toxicity of the liposome-encapsulated doxorubicin (TLC D-99) plus cyclophosphamide (CTX) as first-line treatment of metastatic breast cancer in light of the potential cardioprotective effect of TLC D-99 as compared with conventional doxorubicin. Materials and methods Sixty-seven patients as defined according Simon's two-stage phase II design were enrolled. They received TLC D-99 at the dosage of 60 mg/m2 plus CTX 600 mg/m2, with cycles repeated every 3 weeks. Cardiac function was assessed by ultrasonography at baseline and every two cycles. Results The principal characteristics of the 67 enrolled patients were a…

Adultmedicine.medical_specialtySkin NeoplasmsCyclophosphamideSettore MED/06 - Oncologia MedicaPhases of clinical researchBreast NeoplasmsSoft Tissue NeoplasmsAsymptomaticGastroenterologyDrug Delivery SystemsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAntineoplastic Agents AlkylatingCyclophosphamideAgedAntibiotics AntineoplasticPerformance statusbusiness.industryHematologyMiddle Agedmedicine.diseasedoxorubicin cyclophosphamide breast cancerMetastatic breast cancerSurgeryOncologyDoxorubicinLiposomesToxicityCarcinoma Squamous CellFemalemedicine.symptombusinessmedicine.drug
researchProduct

Mitomycin C from birth to adulthood.

2016

Mitomycin C (MMC) intravesical therapy for “superficial” papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks. In the following decades, many large randomized studies showed the benefit of intravesical prophyla…

Adultmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMitomycinAntibiotics030232 urology & nephrologyUrologyThioTEPASettore MED/24 - Urologia03 medical and health sciencesYoung Adult0302 clinical medicinePharmacokineticsMedicineHumansYoung adultChildComplete responseAntibiotics Antineoplasticbusiness.industryMedicine (all)digestive oral and skin physiologyMitomycin CGeneral MedicineRegimenUrinary Bladder Neoplasms030220 oncology & carcinogenesisUrinary Bladder NeoplasmbusinessAdjuvantHumanmedicine.drugUrologia
researchProduct

Rapid antibiotic susceptibility testing on blood cultures using MALDI-TOF MS

2018

International audience; Antibiotic resistance is a major public health problem requiring the early optimization of antibiotic prescriptions. Matrix-Assisted Laser Desorption Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF MS) has been shown to accurately identify bacteria from positive blood culture. Here, we developed a rapid detection of Escherichia coli resistance to amoxicillin (AMX) and cefotaxime (CTX) from positive blood culture based on MALDI-TOF MS. Potential sparing of broad-spectrum antibiotics was also evaluated. We tested 103 E. coli-positive blood cultures. Blood cultures were subculture 1-hour in antibiotic-free rich liquid media before further incubation with and with…

Agar Dilution Method0301 basic medicineTime FactorsCefotaximePhysiologyAntibioticslcsh:MedicineCefotaximeDrug resistancemedicine.disease_causeMass SpectrometryAnalytical ChemistrySpectrum Analysis TechniquesAntibioticsMicrobial PhysiologyMedicine and Health SciencesBlood cultureMatrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometrylcsh:ScienceMultidisciplinarymedicine.diagnostic_testbiologyAntimicrobialsChemistryMicrobial Growth and DevelopmentDrugsMatrix-Assisted Laser Desorption Ionization Mass SpectrometryBody FluidsAnti-Bacterial Agents3. Good healthChemistryBlood[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyPhysical SciencesAnatomyResearch Articlemedicine.drugmedicine.drug_class030106 microbiologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyAntibiotic Susceptibility TestingMicrobiology03 medical and health sciencesMicrobial ControlDrug Resistance BacterialEscherichia colimedicineHumansEscherichia coliPharmacologyBacteriological TechniquesBacterial Growthlcsh:RBiology and Life SciencesAmoxicillinAmoxicillinbiology.organism_classificationPharmacologic AnalysisBlood CultureAntibiotic ResistanceSpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationlcsh:QAntimicrobial ResistanceSubculture (biology)BacteriaDevelopmental BiologyPLOS ONE
researchProduct

Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)

2019

Abstract Background dNLR is a novel biomarker associated with clinical outcome in solid tumors including early stage breast cancer (BC). Here we report the association of dNLR with pCR in triple-negative (TN) and luminal BC patients (pts) treated with neoadjuvant CT. Methods This was a retrospective analysis of two randomized studies (GEICAM/2006-03 - NCT00432172 and ETNA - NCT01822314) involving 821 pts with early stage (>2cm) or locally advanced TN or luminal BC receiving anthracycline/taxane-based CT +/- carboplatin (GEICAM/2006-03) or nab-paclitaxel/paclitaxel followed by anthracycline regimen (ETNA). dNLR was calculated as the ratio of neutrophils and the difference between total leuko…

Anthracycline Antibioticsmedicine.medical_specialtybusiness.industryLocally advancedHematologyBreast cancer stage iPeripheral bloodInterval dataContinuous variableOncologyFamily medicineRetrospective analysisMedicinebusinesshealth care economics and organizationsComplete responseAnnals of Oncology
researchProduct

Bacterial metal nanoparticles to develop new weapons against bacterial biofilms and infections

2021

The widespread use of antibiotics has resulted in the outbreak and spread of antibiotic-resistant pathogens. Bacterial antibiotic resistance may develop at cellular and community levels. In the latter case, it is based on tolerance which implicates the shift from a free-living form of life (i.e., planktonic) to a sessile multi-stratified community (i.e., biofilm). Metal nanoparticles (MNPs) have been shown to be promising candidates as antimicrobial agents. MNPs are able to interact with and penetrate bacterial biofilms, thus, resulting effective antibiofilm compounds. Another interesting aspect is the possibility of using plants, fungi, yeasts, and bacteria to obtain biogenic MNPs (BMNP). …

Antibiotic resistancemedicine.drug_classAntibioticsMetal NanoparticlesMicrobial Sensitivity TestsApplied Microbiology and BiotechnologyMicrobiologyGreen synthesis03 medical and health sciencesAntibiotic resistanceDrug Resistance BacterialmedicineHumansMetal nanoparticles030304 developmental biology0303 health sciencesBacteriabiology030306 microbiologyChemistryBiofilmBacterial InfectionsGeneral MedicineAntimicrobialbiology.organism_classificationAnti-Bacterial AgentsAntibiofilm activityBiofilmsState of artBiogenic metal nanoparticlesEffluxBacteriaBiotechnologyApplied Microbiology and Biotechnology
researchProduct

Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance

2018

Abstract Biofilm formation significantly contributes to microbial survival in hostile environments and it is currently considered a key virulence factor for pathogens responsible for serious chronic infections. In the last decade many efforts have been made to identify new agents able to modulate bacterial biofilm life cycle, and many compounds have shown interesting activities in inhibiting biofilm formation or in dispersing pre-formed biofilms. However, only a few of these compounds were tested using in vivo models for their clinical significance. Contrary to conventional antibiotics, most of the anti-biofilm compounds act as anti-virulence agents as they do not affect bacterial growth. I…

Antibiotic resistancemedicine.drug_classAntibioticsMicrobial Sensitivity TestsBacterial growthDispersal agent01 natural sciencesVirulence factorMicrobiologySmall Molecule LibrariesStructure-Activity Relationship03 medical and health sciencesAntibiotic resistanceSmall Molecule LibrarieAnti-Bacterial AgentDrug Discoverymedicine030304 developmental biologyPharmacology0303 health sciencesBacteriaDose-Response Relationship DrugMolecular StructureMicrobial Sensitivity Test010405 organic chemistryChemistryBiofilmOrganic ChemistryBiofilmDrug Resistance MicrobialGeneral Medicinebiochemical phenomena metabolism and nutritionAnti-biofilm agentSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeAnti-Bacterial Agents0104 chemical sciencesAnti-adhesion agentBiofilmsAnti-virulence compoundAnti biofilmEuropean Journal of Medicinal Chemistry
researchProduct

Permeability of the rat bladder to Cisplatinum under different conditions: comparison with Mitomycin C and Adriamycin.

1983

In 50 female Sprague-Dawley rats the absorption of Cisplatinum through the bladder wall was studied. Under different conditions, including cystitis and electrocoagulation of the bladder mucosa, the absorption was low and the measureable serum concentrations did not exceed 2.64 micrograms/ml. The influence of Tween 80--a non-ionic surfactant--on the absorption is investigated. The results are compared with those found for Adriamycin and Mitomycin C under identical conditions.

Antibiotics AntineoplasticChemistryUrologymedicine.medical_treatmentMitomycinMitomycin CBladder MucosaUrinary BladderRats Inbred StrainsPharmacologySerum concentrationElectrocoagulationPermeabilityMitomycinsRatsPulmonary surfactantDoxorubicinAnesthesiaCystitismedicineElectrocoagulationAnimalsCisplatinRat BladderUrological research
researchProduct

Synthesis, biological evaluation, and molecular docking studies of aldotetronic acid-based LpxC inhibitors

2022

: In order to develop novel inhibitors of the bacterial deacetylase LpxC bearing a substituent to target the UDP binding site of the enzyme, a series of aldotetronic acid-based hydroxamic acids was accessed in chiral pool syntheses starting from 4,6-O-benzylidene-d-glucose and l-arabinitol. The synthesized hydroxamic acids were tested for LpxC inhibitory activity in vitro, revealing benzyl ether 17a ((2S,3S)-4-(benzyloxy)-N,3-dihydroxy-2-[(4-{[4-(morpholinomethyl)phenyl]ethynyl}benzyl)oxy]butanamide) as the most potent LpxC inhibitor. This compound was additionally tested for antibacterial activity against a panel of clinically relevant Gram-negative bacteria, bacterial uptake, and suscepti…

AntibioticsBacterial uptakeLpxC inhibitorsOrganic ChemistryDrug DiscoveryAldotetronic acid derivativesMolecular-docking studiesLasBMolecular BiologyBiochemistrySettore CHIM/08 - Chimica Farmaceutica
researchProduct

Cyclodextrin-based nano-devices for improved antibiotic activity

2017

AntibioticsCyclodextrinSettore CHIM/06 - Chimica OrganicaSettore BIO/19 - Microbiologia Generale
researchProduct

Synergistic effect with antibiotics and inhibition of bacterial biofilm formation by polyaminocyclodextrin-silver nanoparticles

2018

AntibioticsCyclodextrinSettore CHIM/06 - Chimica OrganicaSilver nanoparticlesSettore BIO/19 - Microbiologia Generale
researchProduct